A nanoparticle-enabled blood proteomics test was reported to track tumor hypoxia during radiotherapy and predict benefit in bladder cancer. The study positioned a blood-based assay as a potential companion diagnostic to identify patients whose tumors are oxygen-starved and may respond to hypoxia-modifying strategies, aiming to move beyond imaging-only hypoxia inference.